DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it had successfully completed the preliminary review of information to be contained in the chemistry, manufacturing and control (CMC) module of its proposed New Drug Application (NDA) for Lymphoseek® with the U.S. Food and Drug Administration (FDA). The CMC review with FDA follows earlier reviews of the clinical and pre-clinical data module components under the current Investigational New Drug (IND) process.
